IL6 and COVID-19: The present study showed that the combination of BCc1 and Hep-S nanomedicines along with the standard treatments of COVID-19 reduced IL-6 as an important mediator of CSS and can be studied and evaluated in future clinical phases to present a novel immunomodulator.